{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T20:22:53Z","timestamp":1773433373773,"version":"3.50.1"},"reference-count":173,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Hodgkin\u2019s lymphoma (HL) is a lymphatic neoplasm typically found in the cervical lymph nodes. The disease is multifactorial, and in recent years, the relationships between various vascular molecules have been explored in the field of vascular biology. The connection between vascular biology and HL is intricate and the roles of several pathways remain unclear. This review summarizes the cellular and molecular relationships between vascular biology and HL. Proteins associated with various functions in vascular biology, including cytokines (TNF-\u03b1, IL-1, IL-13, and IL-21), chemokines (CXCL10, CXCL12, and CCL21), adhesion molecules (ELAM-1\/VCAM-1), and growth factors (BDNF\/NT-3, platelet-derived growth factor receptor-\u03b1), have been linked to tumor activity. Notable tumor activities include the induction of paracrine activation of NF-kB-dependent pathways, upregulation of adhesion molecule regulation, genome amplification, and effective loss of antigen presentation mediated by MHC-II. Preclinical study models, primarily those using cell culture, have been optimized for HL. Animal models, particularly mice, are also used as alternatives to complex biological systems, with studies primarily focusing on the physiopathogenic evaluation of the disease. These biomolecules warrant further study because they may shed light on obscure pathways and serve as targets for prevention and\/or treatment interventions.<\/jats:p>","DOI":"10.3390\/cancers15215299","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T01:37:09Z","timestamp":1699234629000},"page":"5299","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Potential Associations between Vascular Biology and Hodgkin\u2019s Lymphoma: An Overview"],"prefix":"10.3390","volume":"15","author":[{"given":"Wellington Francisco","family":"Rodrigues","sequence":"first","affiliation":[{"name":"Postgraduate Course in Tropical Medicine and Infectious Diseases, Federal University of Triangulo Mineiro, UFTM, Uberaba 38025-440, MG, Brazil"},{"name":"University Center of Mineiros, Unifimes, Mineiros 75833-130, GO, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila Botelho","family":"Miguel","sequence":"additional","affiliation":[{"name":"Postgraduate Course in Tropical Medicine and Infectious Diseases, Federal University of Triangulo Mineiro, UFTM, Uberaba 38025-440, MG, Brazil"},{"name":"University Center of Mineiros, Unifimes, Mineiros 75833-130, GO, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa Carvalho Martins de","family":"Abreu","sequence":"additional","affiliation":[{"name":"University Center of Mineiros, Unifimes, Mineiros 75833-130, GO, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamil Miguel","family":"Neto","sequence":"additional","affiliation":[{"name":"University Center of Mineiros, Unifimes, Mineiros 75833-130, GO, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2211-7333","authenticated-orcid":false,"given":"Carlo Jos\u00e9 Freire","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Postgraduate Course in Tropical Medicine and Infectious Diseases, Federal University of Triangulo Mineiro, UFTM, Uberaba 38025-440, MG, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,6]]},"reference":[{"key":"ref_1","unstructured":"Kaseb, H., and Babiker, H.M. (2022). Hodgkin Lymphoma, StatPearls Publishing."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"C.A. Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13045-022-01281-9","article-title":"Incidence, Mortality, Risk Factors, and Trends for Hodgkin Lymphoma: A Global Data Analysis","volume":"15","author":"Huang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.canlet.2015.10.007","article-title":"Microenvironmental Interactions in Classical Hodgkin Lymphoma and Their Role in Promoting Tumor Growth, Immune Escape and Drug Resistance","volume":"380","author":"Aldinucci","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"a034819","DOI":"10.1101\/cshperspect.a034819","article-title":"Epidemiology and Etiology of Leukemia and Lymphoma","volume":"10","author":"Bispo","year":"2020","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.exphem.2013.09.014","article-title":"Immunologic Pathomechanism of Hodgkin\u2019s Lymphoma","volume":"41","author":"Jona","year":"2013","journal-title":"Exp. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1038\/leu.2014.201","article-title":"The Mutational Landscape of Hodgkin Lymphoma Cell Lines Determined by Whole-Exome Sequencing","volume":"28","author":"Liu","year":"2014","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1158\/1055-9965.EPI-14-0683","article-title":"Genetic Associations in Classical Hodgkin Lymphoma: A Systematic Review and Insights into Susceptibility Mechanisms","volume":"23","author":"Kushekhar","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood.2019000568","article-title":"An Etiological Role for the Epstein-Barr Virus in the Pathogenesis of Classical Hodgkin Lymphoma","volume":"134","author":"Murray","year":"2019","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Nohtani, M., Vrzalikova, K., Ibrahim, M., Powell, J.E., Fennell, \u00c9., Morgan, S., Grundy, R., McCarthy, K., Dewberry, S., and Bouchal, J. (2022). Impact of Tumor Epstein-Barr Virus Status on Clinical Outcome in Patients with Classical Hodgkin Lymphoma (cHL): A Review of the Literature and Analysis of a Clinical Trial Cohort of Children with cHL. Cancers, 14.","DOI":"10.3390\/cancers14174297"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"100949","DOI":"10.1016\/j.blre.2022.100949","article-title":"A Review of Pathobiology and Therapies for Classic Hodgkin Lymphoma","volume":"55","author":"Khan","year":"2022","journal-title":"Blood Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.canlet.2016.05.012","article-title":"Role of the Tumor Microenvironment in Regulating Apoptosis and Cancer Progression","volume":"378","author":"Yaacoub","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e633","DOI":"10.1097\/HS9.0000000000000633","article-title":"Neutrophil and Eosinophil Extracellular Traps in Hodgkin Lymphoma","volume":"5","author":"Francischetti","year":"2021","journal-title":"Hemasphere"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/path.1711710210","article-title":"Vascular Activation in the Histopathogenesis of Hodgkin\u2019s Disease: Potential Role of Endothelial Tissue Factor in Intravascular Thrombosis and Necrosis","volume":"171","author":"Ruco","year":"1993","journal-title":"J. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1634\/theoncologist.6-suppl_5-32","article-title":"The Vascular Endothelial Growth Factor (VEGF) Signaling Pathway: A Therapeutic Target in Patients with Hematologic Malignancies","volume":"6","author":"Giles","year":"2001","journal-title":"Oncologist"},{"key":"ref_16","first-page":"7034","article-title":"Selection of New Immunotherapy Targets for NK\/T Cell Lymphoma","volume":"12","author":"Lv","year":"2020","journal-title":"Am. J. Transl. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/MBC.0000000000001031","article-title":"Assessment of Endothelial Progenitor Cells, VEGF-A and SDF-1\u03b1 in Hodgkin\u2019s Lymphoma","volume":"32","author":"Filipiak","year":"2021","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1080\/10428194.2019.1636982","article-title":"Prediction of Delayed Platelet Engraftment After Autologous Stem Cell Transplantation for B-Cell Non-Hodgkin Lymphoma","volume":"60","author":"Yamaguchi","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Stein, G.S., and Luebbers, K.P. (2019). Cancer: Prevention, Early Detection, Treatment and Recovery, John Wiley & Sons.","DOI":"10.1002\/9781119645214"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/jnci\/83.24.1797-a","article-title":"Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer","volume":"83","author":"Holmes","year":"1991","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_21","unstructured":"Kaplan, H.S. (1980). Hodgkin\u2019s Disease, Harvard University Press. [2nd ed.]."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0140-6736(03)12777-8","article-title":"Hodgkin\u2019s Lymphoma","volume":"361","author":"Yung","year":"2003","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/labinvest.3700528","article-title":"I\u03baB\u03b1 Independent Induction of NF-\u03baB and Its Inhibition by DHMEQ in Hodgkin\/Reed-Sternberg Cells","volume":"87","author":"Watanabe","year":"2007","journal-title":"Lab. Investig."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1053\/j.seminoncol.2008.07.008","article-title":"Progress in Childhood Cancer: 50 Years of Research Collaboration, a Report from the Children\u2019s Oncology Group","volume":"35","author":"Krailo","year":"2008","journal-title":"Semin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich\u2019s Magic Bullet Concept: 100 Years of Progress","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","article-title":"Flow Sorting and Exome Sequencing Reveal the Oncogenome of Primary Hodgkin and Reed-Sternberg Cells","volume":"125","author":"Reichel","year":"2015","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1200\/JCO.2009.27.0421","article-title":"Outcomes for Children and Adolescents with Cancer: Challenges for the Twenty-First Century","volume":"28","author":"Smith","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrc3774","article-title":"The Tumor Microenvironment in B Cell Lymphomas","volume":"14","author":"Scott","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6428","DOI":"10.1158\/1078-0432.CCR-11-0488","article-title":"Brentuximab Vedotin (SGN-35)","volume":"17","author":"Katz","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/intimm\/dxw021","article-title":"Rational Bases for the Use of the Immunoscore in Routine Clinical Settings as a Prognostic and Predictive Biomarker in Cancer Patients","volume":"28","author":"Kirilovsky","year":"2016","journal-title":"Int. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6661406","DOI":"10.1155\/2021\/6661406","article-title":"Current and Future Perspectives of PD-1\/PDL-1 Blockade in Cancer Immunotherapy","volume":"2021","author":"Makuku","year":"2021","journal-title":"J. Immunol. Res."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Al-Tashi, Q., Saad, M.B., Muneer, A., Qureshi, R., Mirjalili, S., Sheshadri, A., Le, X., Vokes, N.I., Zhang, J., and Wu, J. (2023). Machine Learning Models for the Identification of Prognostic and Predictive Cancer Biomarkers: A Systematic Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24097781"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/09537329508524202","article-title":"Foresight in Science and Technology","volume":"7","author":"Martin","year":"1995","journal-title":"Technol. Anal. Strateg. Manag."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"50","DOI":"10.16943\/ijhs\/2019\/v54i1\/49597","article-title":"The Relationship Between Science and Technology and Evolution in Methods of Knowledge Production","volume":"54","author":"Grover","year":"2019","journal-title":"Indian J. Hist. Sci."},{"key":"ref_35","unstructured":"Aggarwal, P., and Limaiem, F. (2023). StatPearls [Internet], STatPearls Publishing."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.biocel.2003.10.025","article-title":"The Hodgkin and Reed\/Sternberg Cell","volume":"37","author":"Hansmann","year":"2005","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/00000478-199910000-00008","article-title":"Peripheral T-Cell Lymphoma with Reed-Sternberg-Like Cells of B-Cell Phenotype and Genotype Associated with Epstein-Barr Virus Infection","volume":"23","author":"Fend","year":"1999","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1146\/annurev.immunol.16.1.471","article-title":"The Origin of Hodgkin and Reed\/Sternberg Cells in Hodgkin\u2019s Disease","volume":"16","author":"Rajewsky","year":"1998","journal-title":"Annu. Rev. Immunol."},{"key":"ref_39","first-page":"701","article-title":"Expression of B-Cell Antigens by Hodgkin\u2019s and Reed-Sternberg Cells","volume":"139","author":"Schmid","year":"1991","journal-title":"Am. J. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1021\/ac101065b","article-title":"Multiplexed Detection and Characterization of Rare Tumor Cells in Hodgkin\u2019s Lymphoma with Multicolor Quantum Dots","volume":"82","author":"Liu","year":"2010","journal-title":"Anal. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1182\/blood-2009-12-257345","article-title":"Genome-Wide Copy Number Analysis of Hodgkin Reed-Sternberg Cells Identifies Recurrent Imbalances with Correlations to Treatment Outcome","volume":"116","author":"Steidl","year":"2010","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Dumitru, A.V., \u021a\u0103poi, D.A., Halcu, G., Munteanu, O., Dumitrascu, D.I., Ceau\u0219u, M.C., and Gheorghi\u0219an-G\u0103l\u0103\u021beanu, A.A. (2023). The Polyvalent Role of CD30 for Cancer Diagnosis and Treatment. Cells, 12.","DOI":"10.3390\/cells12131783"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Bertuzzi, C., Sabattini, E., and Agostinelli, C. (2021). Immune Microenvironment Features and Dynamics in Hodgkin Lymphoma. Cancers, 13.","DOI":"10.3390\/cancers13143634"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3389\/fonc.2018.00288","article-title":"Microenvironment Cell Contribution to Lymphoma Immunity","volume":"8","author":"Kumar","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1136\/jcp.55.3.162","article-title":"Hodgkin\u2019s Lymphoma: The Pathologist\u2019s Viewpoint","volume":"55","author":"Pileri","year":"2002","journal-title":"J. Clin. Pathol."},{"key":"ref_46","unstructured":"Singh, M., Balhara, K., Rana, D., Kumar, R., Dhankar, N., Singh, S., Bellichukki, P., Paul, S., and Chartian, S.M. (2023). Advances in Fine Needle Aspiration Cytopathology, IntechOpen."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Sharma, S.K. (2023). Basics of Hematopoietic Stem Cell Transplant, Springer Nature Publishing.","DOI":"10.1007\/978-981-19-5802-1"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/path.2711","article-title":"The Classical Hodgkin\u2019s Lymphoma Microenvironment and Its Role in Promoting Tumour Growth and Immune Escape","volume":"221","author":"Aldinucci","year":"2010","journal-title":"J. Pathol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrc2542","article-title":"The Biology of Hodgkin\u2019s Lymphoma","volume":"9","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Tamma, R., Ingravallo, G., Gaudio, F., d\u2019Amati, A., Masciopinto, P., Bellitti, E., Lorusso, L., Annese, T., Benagiano, V., and Musto, P. (2023). The Tumor Microenvironment in Classic Hodgkin\u2019s Lymphoma in Responder and No-Responder Patients to First Line ABVD Therapy. Cancers, 15.","DOI":"10.3390\/cancers15102803"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Shi, S., Ye, L., Yu, X., Jin, K., and Wu, W. (2023). Focus on Mast Cells in the Tumor Microenvironment: Current Knowledge and Future Directions. Biochim. Biophys. Acta Rev. Cancer, 1878.","DOI":"10.1016\/j.bbcan.2022.188845"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41375-021-01204-6","article-title":"Molecular Biology of Hodgkin Lymphoma","volume":"35","author":"Weniger","year":"2021","journal-title":"Leukemia"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Men\u00e9ndez, V., Sol\u00f3rzano, J.L., Fern\u00e1ndez, S., Montalb\u00e1n, C., and Garc\u00eda, J.F. (2022). The Hodgkin Lymphoma Immune Microenvironment: Turning Bad News into Good. Cancers, 14.","DOI":"10.3390\/cancers14051360"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Calabretta, E., d\u2019Amore, F., and Carlo-Stella, C. (2019). Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20215503"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41572-021-00319-5","article-title":"Author Correction: Hodgkin Lymphoma","volume":"7","author":"Connors","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Das, K., Mukherjee, T., and Shankar, P. (2023). The Role of Extracellular Vesicles in the Pathogenesis of Hematological Malignancies: Interaction with Tumor Microenvironment; a Potential Biomarker and Targeted Therapy. Biomolecules, 13.","DOI":"10.3390\/biom13060897"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Gusak, A., Fedorova, L., Lepik, K., Volkov, N., Popova, M., Moiseev, I., Mikhailova, N., Baykov, V., and Kulagin, A. (2021). Immunosuppressive Microenvironment and Efficacy of PD-1 Inhibitors in Relapsed\/Refractory Classic Hodgkin Lymphoma: Checkpoint Molecules Landscape and Macrophage Populations. Cancers, 13.","DOI":"10.3390\/cancers13225676"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1203470","DOI":"10.3389\/fonc.2023.1203470","article-title":"Tackling the Dysregulated Immune-Checkpoints in Classical Hodgkin Lymphoma: Bidirectional Regulations Between the Microenvironment and Hodgkin\/Reed-Sternberg Cells","volume":"13","author":"Cellini","year":"2023","journal-title":"Front. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"101931","DOI":"10.1016\/j.ctrv.2019.101931","article-title":"Primary and Acquired Resistance Mechanisms to Immune Checkpoint Inhibition in Hodgkin Lymphoma","volume":"82","author":"Veldman","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e1311","DOI":"10.1002\/cnr2.1311","article-title":"The Circuitry of the Tumor Microenvironment in Adult and Pediatric Hodgkin Lymphoma: Cellular Composition, Cytokine Profile, EBV, and Exosomes","volume":"4","author":"Nagpal","year":"2021","journal-title":"Cancer Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e12712","DOI":"10.1111\/cpr.12712","article-title":"Immune Modulation by Mesenchymal Stem Cells","volume":"53","author":"Jiang","year":"2020","journal-title":"Cell Prolif."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.semcancer.2013.07.002","article-title":"The Microenvironment in Classical Hodgkin Lymphoma: An Actively Shaped and Essential Tumor Component","volume":"24","author":"Liu","year":"2014","journal-title":"Semin. Cancer Biol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Petty, A.J., and Yang, Y. (2019). Tumor-Associated Macrophages in Hematologic Malignancies: New Insights and Targeted Therapies. Cells, 8.","DOI":"10.3390\/cells8121526"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1182\/blood-2002-01-0099","article-title":"The Role of Cytokines in Classical Hodgkin Lymphoma","volume":"99","author":"Skinnider","year":"2002","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Zijtregtop, E.A.M., van der Strate, I., Beishuizen, A., Zwaan, C.M., Scheijde-Vermeulen, M.A., Brandsma, A.M., and Meyer-Wentrup, F. (2021). Biology and Clinical Applicability of Plasma Thymus and Activation-Regulated Chemokine (Tarc) in Classical Hodgkin Lymphoma. Cancers, 13.","DOI":"10.3390\/cancers13040884"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"591741","DOI":"10.3389\/fimmu.2020.591741","article-title":"Angiogenesis in Lymph Nodes Is a Critical Regulator of Immune Response and Lymphoma Growth","volume":"11","author":"Menzel","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"679","DOI":"10.4049\/jimmunol.140.2.679","article-title":"Characterization and Growth Factor Requirements of SJL Lymphomas. I. Development of a B Cell Growth Factor-Dependent In Vitro Cell Line, cRCS-X","volume":"140","author":"Lasky","year":"1988","journal-title":"J. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Ribatti, D., Tamma, R., Annese, T., d\u2019Amati, A., Ingravallo, G., and Specchia, G. (2023). Vascular Growth in Lymphomas: Angiogenesis and Alternative Ways. Cancers, 15.","DOI":"10.3390\/cancers15123262"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e1085","DOI":"10.1002\/hsr2.1085","article-title":"Venous Thromboembolism in Viral Diseases: A Comprehensive Literature Review","volume":"6","author":"Zerangian","year":"2023","journal-title":"Health Sci. Rep."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Jing, H., Wu, X., Xiang, M., Wang, C., Novakovic, V.A., and Shi, J. (2023). Microparticle Phosphatidylserine Mediates Coagulation: Involvement in Tumor Progression and Metastasis. Cancers, 15.","DOI":"10.3390\/cancers15071957"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1172\/JCI61245","article-title":"Hodgkin Lymphoma","volume":"122","author":"Engert","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12964-022-00951-y","article-title":"The Roles of Metabolic Profiles and Intracellular Signaling Pathways of Tumor Microenvironment Cells in Angiogenesis of Solid Tumors","volume":"20","author":"Zalpoor","year":"2022","journal-title":"Cell Commun. Signal."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev.pathol.4.110807.092209","article-title":"Pathogenesis of Classical and Lymphocyte-Predominant Hodgkin Lymphoma","volume":"4","author":"Schmitz","year":"2009","journal-title":"Annu. Rev. Pathol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s10495-022-01780-7","article-title":"BCL-2 Protein Family: Attractive Targets for Cancer Therapy","volume":"28","author":"Kaloni","year":"2023","journal-title":"Apoptosis"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/jcp.27172","article-title":"PD-1\/PD-L1 Immune Checkpoint: Potential Target for Cancer Therapy","volume":"234","author":"Dermani","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1113\/JP280572","article-title":"Regulation of Glycolysis by the Hypoxia-Inducible Factor (HIF): Implications for Cellular Physiology","volume":"599","author":"Kierans","year":"2021","journal-title":"J. Physiol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Aldinucci, D., Borghese, C., and Casagrande, N. (2019). Formation of the Immunosuppressive Microenvironment of Classic Hodgkin Lymphoma and Therapeutic Approaches to Counter It. Int. J. Mol. Sci., 20.","DOI":"10.20944\/preprints201904.0209.v1"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Herraez, I., Bento, L., Del Campo, R., Sas, A., Ramos, R., Ibarra, J., Mestre, F., Alemany, R., Bargay, J., and Sampol, A. (2020). Prognostic Role of the Red Blood Cell Distribution Width (RDW) in Hodgkin Lymphoma. Cancers, 12.","DOI":"10.3390\/cancers12113262"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/pbc.24082","article-title":"Pilot Study of Vascular Health in Survivors of Hodgkin Lymphoma","volume":"59","author":"Mulrooney","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/2052-8426-2-27","article-title":"Gene Therapy for Cancer: Present Status and Future Perspective","volume":"2","author":"Amer","year":"2014","journal-title":"Mol. Cell. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1161\/CIRCULATIONAHA.116.023513","article-title":"The Future of Vascular Biology and Medicine","volume":"133","author":"Kinlay","year":"2016","journal-title":"Circulation"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nrd.2018.169","article-title":"Targeting Macrophages: Therapeutic Approaches in Cancer","volume":"17","author":"Cassetta","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1586\/14737159.7.6.805","article-title":"Recent Insights into the Biology of Hodgkin Lymphoma: Unraveling the Mysteries of the Reed-Sternberg Cell","volume":"7","author":"Roullet","year":"2007","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.it.2011.10.004","article-title":"TNF Superfamily in Inflammatory Disease: Translating Basic Insights","volume":"33","author":"Croft","year":"2012","journal-title":"Trends Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s13402-019-00453-z","article-title":"Tumor-Associated Macrophages: Role in Cancer Development and Therapeutic Implications","volume":"42","author":"Salmaninejad","year":"2019","journal-title":"Cell. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jaci.2016.06.033","article-title":"Interleukins (from IL-1 to IL-38), Interferons, Transforming Growth Factor \u03b2, and TNF-\u03b1: Receptors, Functions, and Roles in Diseases","volume":"138","author":"Akdis","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1399-0039.2009.01382.x","article-title":"IL-21: Roles in Immunopathology and Cancer Therapy","volume":"74","author":"Skak","year":"2009","journal-title":"Tissue Antigens"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrd4296","article-title":"Interleukin-21: A Double-Edged Sword with Therapeutic Potential","volume":"13","author":"Spolski","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0049-3848(00)00332-7","article-title":"Down-Regulation of Murine Tissue Factor Pathway Inhibitor mRNA by Endotoxin and Tumor Necrosis Factor-\u03b1 In Vitro and In Vivo","volume":"100","author":"Shimokawa","year":"2000","journal-title":"Thromb. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1006\/cyto.1999.0533","article-title":"High Altitude Increases Circulating Interleukin-6, Interleukin-1 Receptor Antagonist and C-Reactive Protein","volume":"12","author":"Hartmann","year":"2000","journal-title":"Cytokine"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Wautier, J.L., and Wautier, M.P. (2022). Vascular Permeability in Diseases. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073645"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.molimm.2022.10.001","article-title":"The Mechanism Underlying ICAM-1 and E-selectin-Mediated Hypertriglyceridemic Pancreatitis-Associated Lung Injury","volume":"152","author":"Yu","year":"2022","journal-title":"Mol. Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"954992","DOI":"10.3389\/fimmu.2022.954992","article-title":"Managing the TME to Improve the Efficacy of Cancer Therapy","volume":"13","author":"Bilotta","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1182\/blood.V88.4.1457.bloodjournal8841457","article-title":"Protease Receptors in Hodgkin\u2019s Disease: Expression of the Factor Xa Receptor, Effector Cell Protease Receptor-1, in Reed-Sternberg Cells","volume":"88","author":"Adida","year":"1996","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2174\/1871523020666210920100707","article-title":"Inflammation in Asthma Pathogenesis: Role of T Cells, Macrophages, Epithelial Cells and Type 2 Inflammation","volume":"20","author":"Alobaidi","year":"2021","journal-title":"Antiinflamm. Antiallergy. Agents Med. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/aje\/kwp383","article-title":"Tumor Necrosis Factor (TNF) and Lymphotoxin-\u03b1 (LTA) Polymorphisms and Risk of Non-Hodgkin Lymphoma in the InterLymph Consortium","volume":"171","author":"Skibola","year":"2010","journal-title":"Am. J. Epidemiol."},{"key":"ref_97","first-page":"756353","article-title":"Role of Immune Escape Mechanisms in Hodgkin\u2019s Lymphoma Development and Progression: A Whole New World with Therapeutic Implications","volume":"2012","author":"Lejeune","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Watanabe, T. (2021). Approaches of the Innate Immune System to Ameliorate Adaptive Immunotherapy for B-Cell Non-Hodgkin Lymphoma in Their Microenvironment. Cancers, 14.","DOI":"10.3390\/cancers14010141"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Pe\u00f1a-Romero, A.C., and Orenes-Pi\u00f1ero, E. (2022). Dual Effect of Immune Cells within Tumor Microenvironment: Pro- and Anti-tumor Effects and Their Triggers. Cancers, 14.","DOI":"10.3390\/cancers14071681"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Luo, L., Liu, Y., Chen, D., Chen, F., Lan, H.B., and Xie, C. (2018). CD30 Is Highly Expressed in Chronic Obstructive Pulmonary Disease and Induces the Pulmonary Vascular Remodeling. BioMed Res. Int., 2018.","DOI":"10.1155\/2018\/3261436"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC Class II Transactivator CIITA Is a Recurrent Gene Fusion Partner in Lymphoid Cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/sj.bjp.0701433","article-title":"Chemokine Production by Human Vascular Smooth Muscle Cells: Modulation by IL-13","volume":"122","author":"Jordan","year":"1997","journal-title":"Br. J. Pharmacol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"799","DOI":"10.4049\/jimmunol.154.2.799","article-title":"IL-13 Selectively Induces Vascular Cell Adhesion Molecule-1 Expression in Human Endothelial Cells","volume":"154","author":"Bochner","year":"1995","journal-title":"J. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1016\/S0021-9258(17)41838-2","article-title":"Molecular Cloning of Effector Cell Protease receptor-1, a Novel Cell Surface Receptor for the Protease Factor Xa","volume":"269","author":"Altieri","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2014-05-576140","article-title":"Reed-Sternberg Cell\u2013Derived Lymphotoxin-\u03b1 Activates Endothelial Cells to Enhance T-Cell Recruitment in Classical Hodgkin Lymphoma","volume":"124","author":"Fhu","year":"2014","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00262-008-0528-z","article-title":"Expression and Function of T Cell Homing Molecules in Hodgkin\u2019s Lymphoma","volume":"58","author":"Machado","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/ni1443","article-title":"The Function of Programmed Cell Death 1 and Its Ligands in Regulating Autoimmunity and Infection","volume":"8","author":"Sharpe","year":"2007","journal-title":"Nat. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/path.4459","article-title":"The Epstein-Barr Virus and the Pathogenesis of Lymphoma","volume":"235","author":"Vockerodt","year":"2015","journal-title":"J. Pathol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1568-9972(03)00091-0","article-title":"Pathogenesis of Hemophagocytic Syndrome (HPS)","volume":"3","author":"Larroche","year":"2004","journal-title":"Autoimmun. Rev."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1101\/gad.1653708","article-title":"Role of Platelet-Derived Growth Factors in Physiology and Medicine","volume":"22","author":"Andrae","year":"2008","journal-title":"Genes Dev."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0301-472X(02)00791-9","article-title":"Platelet-Derived Microparticles Stimulate Proliferation, Survival, Adhesion, and Chemotaxis of Hematopoietic Cells","volume":"30","author":"Majka","year":"2002","journal-title":"Exp. Hematol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1093\/emboj\/16.10.2851","article-title":"Expression of MHC Class II Molecules in Different Cellular and Functional Compartments Is Controlled by Differential Usage of Multiple Promoters of the Transactivator CIITA","volume":"16","author":"Otten","year":"1997","journal-title":"EMBO J."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1111\/cas.14934","article-title":"Development of Humanized Mouse with Patient-Derived Xenografts for Cancer Immunotherapy Studies: A Comprehensive Review","volume":"112","author":"Jin","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Kametani, Y., Ohno, Y., Ohshima, S., Tsuda, B., Yasuda, A., Seki, T., Ito, R., and Tokuda, Y. (2019). Humanized Mice as an Effective Evaluation System for Peptide Vaccines and Immune Checkpoint Inhibitors. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20246337"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.coph.2021.08.008","article-title":"Preclinical Pharmacology Modeling of Chimeric Antigen Receptor T Therapies","volume":"61","author":"Kumari","year":"2021","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_117","unstructured":"Shnyder, S.D., Chatterji, S.K., and El-Khamisy, S. (2022). Paraproteinemia and Related Disorders, Springer."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3324\/haematol.2018.196725","article-title":"CCR5 Antagonism by Maraviroc Inhibits Hodgkin Lymphoma Microenvironment Interactions and Xenograft Growth","volume":"104","author":"Casagrande","year":"2019","journal-title":"Haematologica"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.canlet.2020.12.015","article-title":"Trabectedin Overcomes Doxorubicin-Resistance, Counteracts Tumor-Immunosuppressive Reprogramming of Monocytes and Decreases Xenograft Growth in Hodgkin Lymphoma","volume":"500","author":"Casagrande","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1080\/10428194.2021.2015587","article-title":"Loss of Function Mutations of BCOR in Classical Hodgkin Lymphoma","volume":"63","author":"Giefing","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Sakai, Y., Rezano, A., Okada, S., Ohtsuki, T., Kawashima, Y., Tsukamoto, T., Suzuki, M., Kohara, M., Takeya, M., and Sakaguchi, N. (2020). A Novel Cytological Model of B-Cell\/Macrophage Biphenotypic Cell Hodgkin Lymphoma in ganp-Transgenic Mice. Cancers, 12.","DOI":"10.3390\/cancers12010204"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"150923","DOI":"10.1016\/j.soncn.2019.08.002","article-title":"Cancer and the Immune System: The History and Background of Immunotherapy","volume":"35","author":"Abbott","year":"2019","journal-title":"Semin. Oncol. Nurs."},{"key":"ref_123","first-page":"e41660","article-title":"A Review of Hodgkin Lymphoma in the Era of Checkpoint Inhibitors","volume":"15","author":"Schimmoeller","year":"2023","journal-title":"Cureus"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Nakhoda, S., Rizwan, F., Vistarop, A., and Nejati, R. (2022). Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin\u2019s Lymphoma. Cancers, 14.","DOI":"10.3390\/cancers14122936"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.cjche.2020.11.009","article-title":"Monoclonal Antibody-Based Cancer Therapies","volume":"30","author":"Si","year":"2021","journal-title":"Chin. J. Chem. Eng."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Meier, J.A., Savoldo, B., and Grover, N.S. (2022). The Emerging Role of CAR T Cell Therapy in Relapsed\/Refractory Hodgkin Lymphoma. J. Pers. Med., 12.","DOI":"10.3390\/jpm12020197"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and Immunological Responses After CD30-Specific Chimeric Antigen Receptor-Redirected Lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/bfgp\/elz042","article-title":"Applications and Explorations of CRISPR\/Cas9 in CAR T-Cell Therapy","volume":"19","author":"Li","year":"2020","journal-title":"Brief. Funct. Genom."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/bloodadvances.2021005385","article-title":"Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma","volume":"6","author":"Voorhees","year":"2022","journal-title":"Blood Adv."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.semcancer.2023.02.007","article-title":"Artificial Intelligence in Cancer Immunotherapy: Applications in Neoantigen Recognition, Antibody Design and Immunotherapy Response Prediction","volume":"Volume 91","author":"Li","year":"2023","journal-title":"Seminars in Cancer Biology"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1203073","DOI":"10.3389\/fimmu.2023.1203073","article-title":"Antibody-Drug Conjugates: The Paradigm Shifts in the Targeted Cancer Therapy","volume":"14","author":"Aggarwal","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Karihtala, K., Leivonen, S.K., Br\u00fcck, O., Karjalainen-Lindsberg, M.L., Mustjoki, S., Pellinen, T., and Lepp\u00e4, S. (2020). Prognostic Impact of Tumor-Associated Macrophages on Survival Is Checkpoint Dependent in Classical Hodgkin Lymphoma. Cancers, 12.","DOI":"10.3390\/cancers12040877"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Cencini, E., Fabbri, A., Sicuranza, A., Gozzetti, A., and Bocchia, M. (2021). The Role of Tumor-Associated Macrophages in Hematologic Malignancies. Cancers, 13.","DOI":"10.3390\/cancers13143597"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"215766","DOI":"10.1016\/j.canlet.2022.215766","article-title":"Metabolism and polarization regulation of macrophages in the tumor microenvironment","volume":"543","author":"Wang","year":"2022","journal-title":"Cancer Lett."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1113312","DOI":"10.3389\/fimmu.2023.1113312","article-title":"The role of macrophages-mediated communications among cell compositions of tumor microenvironment in cancer progression","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"154739","DOI":"10.1016\/j.prp.2023.154739","article-title":"Tumor-associated macrophages: Potential therapeutic targets and diagnostic markers in cancer","volume":"249","author":"Song","year":"2023","journal-title":"Pathol. Res. Pract."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"9410","DOI":"10.1038\/s41598-020-66010-z","article-title":"Tumor-associated macrophages in classical Hodgkin lymphoma: Hormetic relationship to outcome","volume":"10","author":"Werner","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"109235","DOI":"10.1016\/j.intimp.2022.109235","article-title":"Tumor-associated macrophages in lymphoma: From mechanisms to therapy","volume":"112","author":"Xiong","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.2217\/nnm-2021-0255","article-title":"Immunotherapy for cancer: Effects of iron oxide nanoparticles on polarization of tumor-associated macrophages","volume":"16","author":"Nascimento","year":"2021","journal-title":"Nanomedicine"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/cac2.12345","article-title":"Tumor-associated macrophages in liver cancer: From mechanisms to therapy","volume":"42","author":"Cheng","year":"2022","journal-title":"Cancer Commun."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2147\/DDDT.S253232","article-title":"Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development","volume":"14","author":"Benner","year":"2020","journal-title":"Drug. Des. Devel. Ther."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e006262","DOI":"10.1136\/jitc-2022-006262","article-title":"Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)","volume":"11","author":"Siddiqui","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/bjh.18348","article-title":"Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single-center phase II study","volume":"198","author":"Picardi","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Yang, S., Shim, M.K., Kim, W.J., Choi, J., Nam, G.H., Kim, J., Kim, J., Moon, Y., Kim, H.Y., and Park, J. (2021). Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity. Biomaterials, 272.","DOI":"10.1016\/j.biomaterials.2021.120791"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"672356","DOI":"10.3389\/fimmu.2021.672356","article-title":"Neoantigen: A New Breakthrough in Tumor Immunotherapy","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrc.2016.154","article-title":"Targeting Neoantigens to Augment Antitumour Immunity","volume":"17","author":"Yarchoan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"944511","DOI":"10.3389\/fonc.2022.944511","article-title":"A Phase I Dose-Escalation Study of Neoantigen-Activated Haploidentical T Cell Therapy for the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma","volume":"12","author":"Chen","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.rbmo.2021.08.007","article-title":"Molecular Profiling of Follicular Fluid microRNAs in Young Women Affected by Hodgkin Lymphoma","volume":"43","author":"Caponnetto","year":"2021","journal-title":"Reprod. Biomed. Online"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.copbio.2021.10.015","article-title":"Synthetic mRNA\u2013Emerging New Class of Drug for Tissue Regeneration","volume":"74","author":"Balmayor","year":"2022","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Vavilis, T., Stamoula, E., Ainatzoglou, A., Sachinidis, A., Lamprinou, M., Dardalas, I., and Vizirianakis, I.S. (2023). mRNA in the Context of Protein Replacement Therapy. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15010166"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaoncol.2022.7975","article-title":"Pembrolizumab added to ifosfamide, carboplatin, and etoposide chemotherapy for relapsed or refractory classical Hodgkin lymphoma: A multi-institutional phase 2 Investigator-Initiated Nonrandomized Clinical Trial","volume":"9","author":"Bryan","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/17474086.2021.1942831","article-title":"Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed\/refractory Classical Hodgkin Lymphoma or systemic anaplastic large cell lymphoma","volume":"14","author":"Song","year":"2021","journal-title":"Expert Rev. Hematol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/10428194.2017.1330954","article-title":"Minimal Activity of Nanoparticle Albumin-Bound (Nab) Paclitaxel in Relapsed or Refractory Lymphomas: Results of a Phase-I Study","volume":"59","author":"Goyal","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.bbmt.2019.05.028","article-title":"Results of the first clinical study in humans that combined Hyperbaric Oxygen pretreatment with autologous peripheral blood stem cell transplantation","volume":"25","author":"Abdelhakim","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_157","unstructured":"Gonz\u00e1lez-Ramella, R.\u00d3. (2023, October 23). Enhancing Effect on Tumor Apoptosis with the Use of Pentoxifylline in Patients with Hodgkin Lymphoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05490953."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1080\/10428194.2022.2095623","article-title":"AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: Final results of an open-label, randomized, multicenter phase II trial","volume":"63","author":"Sasse","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2206660","article-title":"Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin\u2019s Lymphoma","volume":"387","author":"Castellino","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/bloodadvances.2021004970","article-title":"Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed\/refractory classical Hodgkin lymphoma","volume":"6","author":"Zinzani","year":"2022","journal-title":"Blood Adv."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/ejh.13859","article-title":"JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open-label, multicenter clinical trial (JeRiCHO)","volume":"109","author":"Gillessen","year":"2022","journal-title":"Eur. J. Haematol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2352-3026(22)00318-0","article-title":"Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: A multicentre, phase 2 trial","volume":"10","author":"Herrera","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"ECHELON-1 Study Group. Overall Survival with brentuximab vedotin for stage III or IV Hodgkin\u2019s Lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e004445","DOI":"10.1136\/jitc-2021-004445","article-title":"Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin\u2019s lymphoma: A phase II, non-randomized controlled trial","volume":"10","author":"Hochberg","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/s41375-021-01421-z","article-title":"Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma","volume":"36","author":"Thelen","year":"2022","journal-title":"Leukemia"},{"key":"ref_166","unstructured":"Cai, Q., and Sun, Y. (2023, October 23). Pianzumab Combined with AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05949931."},{"key":"ref_167","unstructured":"Weidong, H. (2023, October 23). SHR1701 Alone or in Combination with SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05896046."},{"key":"ref_168","unstructured":"Gloria, G. (2023, October 23). GLS-010 Monotherapy versus Chemotherapy in Patients with Relapsed or Refractory Classical Hodgkin\u2019s Lymphoma (R\/R cHL), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05518318."},{"key":"ref_169","unstructured":"Akeso (2023, October 23). A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin\u2019s Lymphoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05244642."},{"key":"ref_170","unstructured":"Sharp, M., and LLC, D. (2023, October 23). A Study of Coformulated Favezelimab\/Pembrolizumab (MK-4280A) versus Physician\u2019s Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05508867."},{"key":"ref_171","unstructured":"Fondazione Italiana Linfomi (ETS) (2023, October 23). Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin\u2019s Lymphoma Patients (FIL_A-BEGEV), Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05300282."},{"key":"ref_172","unstructured":"GmbH, A. (2023, October 23). Phase 2 Study of AFM13 in Combination with AB-101 in Subjects with R\/R HL and CD30+ PTCL (LuminICE-203), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05883449."},{"key":"ref_173","unstructured":"Institute, N.C. (2023, October 23). Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients with Nodular Lymphocyte-Predominant Hodgkin Lymphoma, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT05886036."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/21\/5299\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:18:00Z","timestamp":1760131080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/21\/5299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,6]]},"references-count":173,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["cancers15215299"],"URL":"https:\/\/doi.org\/10.3390\/cancers15215299","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,6]]}}}